Weiss Asset Management’s Immunovant IMVT Stock Holding History

Weiss Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-19,897	Closed	-$170K	–	841
2021 Q4	$170K	Sell	19,897 -10,103	-34%	-$83.4K	﹤0.01%	617
2021 Q3	$261K	Hold	30,000	–	–	0.01%	438
2021 Q2	$317K	Buy	+30,000	New	+$419K	0.01%	434
2019 Q4	–	Sell	-50,400	Closed	-$503K	–	356
2019 Q3	$503K	Buy	50,400 +400	+0.8%	+$3.95K	0.04%	118
2019 Q2	$490K	Buy	+50,000	New	+$494K	0.03%	151

Other funds holding IMVT

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Weiss Asset Management's IMVT Position: Q1 2022 in Review

Weiss Asset Management sold out of Immunovant (IMVT) in Q1 2022, closing a stake of 19,897 shares — an estimated $170K sold.

Weiss Asset Management first reported a position in IMVT in Q2 2019 and held it in 5 quarters. The position peaked at $503K in Q3 2019. 112 funds tracked by Wall St. Rank hold IMVT as of Q1 2022.

Weiss Asset Management reported no remaining Immunovant position as of Q1 2022 after selling out during the quarter.
Weiss Asset Management sold 19,897 Immunovant shares in Q1 2022, an estimated $170K.
Weiss Asset Management first reported a position in Immunovant in Q2 2019 and held it in 5 quarters.
Weiss Asset Management's Immunovant position peaked at $503K in Q3 2019.
112 funds tracked by Wall St. Rank held Immunovant as of Q1 2022.

Based on Weiss Asset Management's 13F filing for Q1 2022, filed 13 May 2022.